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ORIGINAL ARTICLE
Background/Aims: Papillary thyroid cancer (PTC) is the most common malignancy of the thyroid gland. It
involves several molecular mechanisms. The BRAF V600E mutation has been identified as the most common
genetic abnormality in PTC. Moreover, it is known to be more prevalent in Korean PTC patients than in patients
from other countries. We investigated distinct genetic profiles in Korean PTC through cDNA microarray analysis.
Methods: Transcriptional profiles of five PTC samples and five paired normal thyroid tissue samples were
generated using cDNA microarrays. The tumors were genotyped for BRAF mutations. The results of the cDNA
microarray gene expression analysis were confirmed by real-time PCR and immunohistochemistry analysis of 35
PTC patients.
Results: Four of the five patients whose PTC tissues were subjected to microarray analysis were found to carry
the BRAF V600E mutation. Microarrays analysis of the five PTC tissue samples showed the expression of 96
genes to be increased and that of 16 genes decreased. Real-time reverse transcription-polymerase chain reaction
(RT-PCR) confirmed increased expression of SLC34A2, TM7SF4, COMP, KLK7, and KCNJ2 and decreased
expression of FOXA2, SLC4A4, LYVE-1, and TFCP2L1 in PTC compared with normal tissue. Of these genes,
TFCP2L1, LYVE-1, and KLK7 were previously unidentified in PTC microarray analysis. Notably, Foxa2 activity in
PTC was reduced, as shown by its cytoplasmic localization, in immunohistochemical analyses.
Conclusions: These findings demonstrate both similarities and differences between our results and previous
reports. In Korean cases of PTC, Foxa2 activity was reduced with its cytoplasmic accumulation. Further studies
are needed to confirm the relationship between FOXA2 and BRAF mutations in Korean cases of PTC. (Korean J
Intern Med 2010;25:399-407)
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INTRODUCTION
Papillary thyroid cancer (PTC) is the most common
thyroid cancer in iodine-sufficient regions [1]. It is
believed to account for more than 80% of all thyroid
cancers [2,3]. The clinical characteristics of PTC are
diverse, ranging from slow, progressive micro-PTC to
anaplastic cancers [4,5].
Although the pathogenetic mechanisms behind PTC
remain unknown, multiple genes and environmental
factors have been implicated in its development [3,6].
RET/PTC rearrangements, RAS mutations, and BRAF
mutations are known genetic abnormalities in PTC. The
incidences of RET/PTC rearrangements, RAS mutations,
and BRAF mutations in PTC are 13-43%, 0-21%, and 29-
69%, respectively [7]. In Korean PTC patients, RAS
mutations are rare, and BRAF mutation more common
[8].
The gold standard method for diagnosing PTC is fine-
needle aspiration biopsy (FNAB) [9,10]. Nevertheless, 10-15% of FNAB results are inadequate, and 10-20%
indeterminate, making accurate diagnosis of the thyroid
nodules difficult [11]. 
To manage the limitations of FNAB in PTC, many
researchers have attempted to identify useful genetic
tools. One such tool, DNA microarray analysis, is expected
to provide information about the pathogenetic
mechanism and genetics of PTC. According to a meta-
analysis of 21 published thyroid cancer gene expression
profiling studies, in addition to genes such as MET, TFF3,
SERPINA1, TIMP1, FN1, and TPO that have previously
been linked to PTC, other genes such as TGFA, OPCT,
CRABP1, FCGBP, EPS8, and PROS1 showed different
expression between PTC samples and normal tissues [12].
In a separate microarray analysis, PTC cases with
RET/PTC rearrangements, RAS mutations, and BRAF
mutations displayed distinct gene expression profiles [13].
The present study was undertaken in Korean PTC
patients, who showed a high prevalence of BRAF mutati-
ons. Our objective was to identify, in microarray analyses,
genes whose expression was altered in Korean PTC as
candidate diagnostic markers in PTC. 
METHODS
Subjects
PTC tissue samples were obtained intra-operatively
from 35 patients during thyroidectomy procedures
performed between January 2008 and December 2008.
Normal tissue samples were collected from the same
patients for pair-wise analysis. The study protocol was
approved by the Institutional Review Board, and all
patients signed informed consent. 
Isolation of RNA and DNA microarray analysis
Tissue samples obtained during thyroidectomy were
immediately frozen in liquid nitrogen and stored. Total
RNA was extracted using TRIzol (Invitrogen, Camarillo,
CA, USA) and purified using an RNeasy Mini Kit (Qiagen,
Hilden, Germany). Sample purity was confirmed by
measuring A260/A280 ratios, and quality by 1% agarose gel
electrophoresis. RNA samples from five PTC
tissue/normal tissue pairs were chosen for microarray
studies. Biotinylated cRNA was prepared from 0.55 µg of
total RNA using the Illumina TotalPrep RNA
Amplification Kit (Ambion, Austin, TX, USA). Following
fragmentation, 0.75 µg of cRNA was hybridized to
Illumina HumanHT-12 v3 Expression BeadChips
(Illumina Inc., San Diego, CA, USA) according to
protocols provided by the manufacturer.
Real-time RT-PCR analysis
The expression of genes identified in microarray
analyses as being up-regulated (TM7SF4, SLC34A2,
KCNJ2, COMP, and KLK7) and down-regulated
(TFCP2L1, LYVE-1, FOXA2, and SL4A4) in PTC was
examined by real-time reverse transcription-polymerase
chain reaction (RT-PCR). A RevertAid
TM First Strand
cDNA Synthesis Kit (Fermentas, Hanover, MD, USA) was
used to synthesize cDNA. PCR reactions (20 mL)
contained total RNA (2 mg), oligo (dT)18 primer (1 mL), 5
× reaction buffer (4 mL), RiboLock
TM Ribonuclease
Inhibitor (20 u/mL) (1 mL), 10 mM dNTP mix (2 mL),
and RevertAid
TM M-MuLV Reverse Transcriptase (200
u/mL) (1 mL). An ABI PRISM 7500 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA) and
TaqMan probe PCR master mix (Applied Biosystems)
were used in real-time PCR reaction. The PCR
amplification procedure was carried out in 96-well plates
in 20-mL reactions containing cDNA (1 µL), probe (1 µL),
Master Mix (10 µL) and QW (8 µL). The following thermal
conditions were applied: 50°C for 2 minutes; 95°C for 10
minutes; and 40 cycles of 95°C for 15 seconds and 60°C
for 1 minute.
BRAF mutation analysis
BRAF mutation analysis was performed using the five
papillary thyroid cancer tissue samples subjected to
microarray analysis. Genomic DNA was extracted using
G-DEX (iNtRON Biotechnology Co. Ltd., Seoul, Korea).
Exon 15 of BRAF was PCR-amplified using the following
PCR primers: BRAF 15, 5 - ATGTTGCTCTGATAGGAAA
-3 (sense), 5 - GATTTTTGTGAATACTGGGAA -3
(antisense). 
Statistical analysis
Significant differences in gene expression between
cancerous and normal tissues in the microarray analysis
were identified using paired Student's t test, fold-change,
and hierarchical clustering, performed using SPSS version
14.0 (SPSS Inc., Chicago, IL, USA). Differences were
considered statistically significant when the false-
discovery rate (FDR) was 10% of the control (p values
were subjected to Benjamini-Hochberg FDR correction)
and the fold-change was ≥ 2.
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Clinical characteristics of the study patients
The mean patient age was 50.2 ± 13.2 years. The patient
group comprised 3 men and 32 women. The classic PTC
subtype was found in 34 patients, and the follicular
variant in one patient. The mean tumor size was 1.3 ± 0.6
cm. Eighteen cases (50%) showed extrathyroidal invasion,
and 22 cases (66%) showed lymph node metastasis.
BRAF mutations and gene expression in DNA
microarray analysis 
Four of the five PTC samples subjected to microarray
analysis were positive for the T1799A BRAF mutation.
DNA microarray analysis of 5 PTC samples identified 112
genes whose expression showed a more than 2-fold
change and where FDR was 10% of the control in PTC
tissue compared with paired normal tissue. Of these, 96
genes, including TM7SF4, SLC34A2, KCNJ2, C7orf24,
PROS1, SERPINA1, TUSC3, COMP, kallikrein-related
peptidase 7 (KLK7), and matrix metallopeptidase 7,
showed more than 2-fold higher expression in PTC tissues
compared with paired normal tissues (Table 1). Expression
of the remaining 16 genes, which included metallothionein
1F (MT1F), HBA2, ACACB, RYR2, OTOS, SLC4A4,
TFCP2L1, LYVE-1, and FOXA2, was decreased more than
2-fold in PTC tissues compared with paired normal tissue
(Table 1). 
Of the genes previously linked to BRAF mutation-
associated PTC, TM7SF4, SLC34A2, PDE5A, TPD52L1,
FN1, PLXNC1, TMPRSS6, and ERBB3 displayed more
than 2-fold increased expression in PTC tissues, whereas
the expression of ARNTL, PERP, GATA3, IRS2,
CLECSF2, and STAT1 was increased less than 2-fold in
PTC tissues compared with paired normal tissues (Table
2). The expression of TFF3, ARGBP2, HGD, FHL1, IRS1,
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Table 1. Up-regulated or down-regulated genes in microarray analysis of papillary thyroid cancer 
Gene  Fold change
Transmembrane 7 superfamily member 4 (TM7SF4) 20.22
Solute carrier family 34 (sodium phosphate), member 2 (SLC34A2) 14.56
Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 (SERPINA1) 13.25
Cartilage oligomeric matrix protein (COMP) 11.08
Matrix metallopeptidase 7 8.67
Kallikrein-related peptidase 7 (KLK7) 7.01
Protein S (alpha) (PROS1) 5.73
Potassium inwardly-rectifying channel, subfamily J, member 2 (KCNJ2) 5.69
Chromosome 7 open reading frame 24 (C7orf24) 4.27
Tumor suppressor candidate 3 (TUSC3) 4.21
Metallothionein 1F -4.32
Otospiralin (OTOS) -4.11
Forkhead box A2 (FOXA2) -4.04
Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) -3.82
Tanscription factor CP2-like 1 (TFCP2L1) -3.76
Solute carrier family 4, sodium bicarbonate cotransporter, member 4 (SLC4A4) -3.13
Ryanodine receptor 2 (cardiac) (RYR2)  -2.79
Hemoglobin, alpha 2 (HBA2) -2.51
Acetyl-Coenzyme A carboxylase beta (ACACB) -2.04and HLF was decreased more than 2-fold in PTC tissues
compared with paired normal tissues, and that of
GALNT10, HES1, VAV3, MMP 15, PLA2G4B, COL4A5,
ARHN, and DUOX1 less than 2-fold (Table 2).
Functional classification of differently expressed
genes 
We summarized the functional classifications of genes
that were differently expressed in PTC tissues and paired
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Table 2. Genes showing different expressions in this study among known distinct genes for BRAF mutant
papillary thyroid cancer
Gene  Fold change
Transmembrane 7 superfamily member 4 (TM7SF4) 20.22
Solute carrier family 34 (sodium phosphate), member 2 (SLC34A2) 14.56
Transmembrane protease, serine 6 (TMPRSS6) 7.65
Fibronectin 1 (FN1) 5.99
V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (ERBB3) 4.41
Aryl hydrocarbon receptor nuclear translocator-like (ARNTL) 2.84
Tumor protein D52-like 1 (TPD52L1) 2.64
Phosphodiesterase 5A (PDE5A) 2.53
Plexin C1 (PLXNC1) 2.26
TP53 apoptosis effector (PERP) 1.86
Insulin receptor substrate 2 (IRS2) 1.60
Signal transducer and activator of transcription 1, 91kDa (STAT1) 1.43
GATA binding protein 3 (GATA3) 1.08
C-type lectin domain family 2, member B (CLECSF2) 1.07
Trefoil factor 3 (intestinal) (TFF3) -8.50
Sorbin and SH3 domain containing 2 (SORBS2: ARGBP2) -3.67
Homogentisate oxidase (HGD) -3.25
Four and a half LIM domains 1 (FHL1) -2.76
Insulin receptor substrate 1 (IRS1) -2.50
Hepatic leukemia factor (HLF) -2.01
Matrix metallopeptidase 15 (MMP15) -1.48
Slit homolog 3 (SLIT3: ARHN) -1.47
Collagen, type IV, alpha 5 (COL4A5) -1.16
Vav 3 guanine nucleotide exchange factor (VAV3) -1.15
Phospholipase A2, group IVB (PLA2G4B) -1.15
Hairy and enhancer of split 1, (Drosophila) (HES1) -1.04
Dual oxidase 1 (DUOX1) -1.04
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 10 (GALNT10) -1.03Kim HS, et al. Microarray analysis of papillary thyroid cancer  403
normal tissues (Table 3). Of the genes involved in cell-
cycle control, the expression of KLK7, TGFA, and cyclin D1
was increased, whereas that of FOXA2 decreased.
Meanwhile, of the ion-channel genes, the expression of
SLC34A2, KCNJ2, and claudin 16 was increased, and that
of RYR2 decreased. Expression of the adhesion molecules
cadherin 3, NRCAM, POSTN, and ITGA2 was increased.
Real-time RT-PCR analysis of gene expression 
From the genes displaying large differences in
expression between PTC and normal tissues in the
microarray analysis, we selected 9 for which information
was available in PubMed. Microarray analysis showed the
expression of TM7SF4, SLC34A2, KCNJ2, COMP, and
KLK7 to be increased, and that of TFCP2L1, LYVE-1,
FOXA2, and SLC4A4 to be decreased. Real-time RT-PCR
analysis confirmed all these findings (Figs. 1 and 2).
Immunohistochemical analysis of FOXA2, COMP,
and LYVE-1
We studied the products of the FOXA2, COMP, and
LYVE-1 genes immunohistochemically using
commercially available antibodies. LYVE1 and COMP
were found to be only weakly expressed and could not be
fully analyzed. Foxa2 exhibited cytoplasmic expression in
PTC tissues and nuclear expression in paired normal
tissues (Fig. 3). 
DISCUSSION
PTCs exhibit different patterns of gene expression
according to the presence of RET/PTC rearrangements,
RAS mutations, and BRAF mutations. In the present
study, we used DNA microarrays to analyze gene
expression in Korean PTC patients, in whom the
prevalence of BRAF mutations is approximately 80% [8].
The results showed that the expression of 96 genes,
including TM7SF4, SLC34A2, KCNJ2, and KLK7, was
increased more than 2-fold in PTC tissues compared with
paired normal tissues, and that of 16 genes, including
MT1F, FOXA2, TFCP2L1, and LYVE-1, decreased more
than 2-fold. Eszlinger et al. [14] previously identified
shared and distinct gene expression in PTC subtypes
characterized by RET/PTC, BRAF, and RAS mutations.
They identified 20 up- and down-regulated genes in BRAF
Table 3. Functional classification of genes showing altered expression in papillary thyroid cancer
Function Genes
Cell cycle  Up-regulated: KLK7, TGFA, Cyclin D1 
Down-regulated: FOXA2
Cell adhesion molecule Up-regulated: COL8A1, cadherin 3, NRCAM, periostin
Ion channel Up-regulated: KCNJ2, SCN-1B, SLC34A2, claudin 16 
Down-regulated: Ryanodine receptor-2 (RYR2)
Nuclear acid binding Up-regulated: RXRG, BHLHB3, IRX2,  ZMAT3 
Down-regulated: forkhead box A2 (FOXA2)
Receptor Up-regulated: LPAR5, ADORA1, XPR1, RXRG 
Down-regulated: RYR2 
Signaling molecule Up-regulated: MDK, TGFA, COMP, CBLN1
Down-regulated: SEMA6A
Transcription factor Up-regulated: IRX2, RXRG, RUNX1, ETV5, TSC22D1 
Down-regulated: TFCP2L1 
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mutation-associated PTC. Of these genes, we confirmed
the expression of TM7SF4, SLC34A2, PDE5A, TPD52L1,
FN1, PLXNC1, TMPRSS6, and ERBB3 to be increased
more than 2-fold in PTC tissues compared with paired
normal tissues, but found the expression of ARNTL,
PERP, GATA3, IRS2, CLECSF2, and STAT1 to be
increased less than 2-fold in PTC tissues (Table 2). We
also found similar > 2-fold down-regulation of TFF3,
ARGBP2, HGD, FHL1, IRS1, and HLF in PTC tissues
compared with paired normal tissues, but found the
Figure 2. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) of genes that were down-regulated in papillary thyroid
cancer tissues compared with paired normal tissues. FOXA2, forkhead box A2; LYVE-1, lymphatic vessel endothelial hyaluronan receptor
1; SLC4A4, solute carrier family 4, sodium bicarbonate cotransporter, member 4; TFCP2L1, transcription factor CP2-like 1.
Figure 1. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) of genes that were up-regulated in papillary thyroid
cancer tissues compared with paired normal tissues. COMP, cartilage oligomatrix protein; KCNJ2, potassium inwardly-rectifying
channel, subfamily J, member 2; KLK-6, kallikrein-related peptidase 6; KLK-7, kallikrein-related peptidase 7; SLC 34, solute carrier
family 34 (sodium phosphate); TM7SF4, transmembrane 7 superfamily member 4.Kim HS, et al. Microarray analysis of papillary thyroid cancer  405
expression of GALNT10, HES1, VAV3, MMP 15,
PLA2G4B, COL4A5, ARHN, and DUOX1 to be decreased
less than 2-fold in PTC tissues compared with paired
normal tissues (Table 2). Moreover, although we found
that the LYVE1, MT1F, OTOS, and FOXA2 expression was
significantly decreased in PTC tissues compared with
normal tissues, these genes were not among those
showing different expression in the study of BRAF
mutation-associated PTC by Eszlinger et al. [14].
Our study has certain limitations. We did not
specifically measure gene expression in BRAF mutation-
positive PTC. However, four of the five PTC samples that
we subjected to microarray analysis were positive for
BRAF mutations. We therefore consider that our
microarray results show characteristic gene expression
profiles for Korean BRAF mutant PTC. 
To confirm our initial findings, we analyzed a subset of
genes showing altered expression in the microarray
analysis by real-time RT-PCR. The results of this real-time
RT-PCR confirmed the findings of the microarray
analysis, showing the expression of TM7SF4, KCNJ2,
SLC34A2, KLK7, and COMP to be increased in PTC
tissues compared with normal tissues and that of FOXA2,
LYVE-1, TFCP2L1, and SLC4A4 to be decreased.
First identified in dendritic cells [15], TM7SF4 (DC-
STAMP) is also expressed in osteoclasts and is required
for osteoclast cell fusion and monocyte-derived
multinucleated giant cell formation [16]. A previous study
employing the GeneFishing method reported that
expression of the TM7SF4 and COL1A1 genes was
significantly different in PTC tissues compared with
normal tissues [17]. In addition, Galeza-Kulik et al. [18]
analyzed tissue from 38 PTC patients by quantitative real-
time PCR and identified several genes involved in the
transport of ions whose expression was altered in PTC.
They reported increased SLC34A2 and KCNJ2 expression
and reduced SLC4A4 expression in PTC tissues. The
results of our microarray and real-time RT-PCR analyses
confirmed the expression of SLC34A2 and KCNJ2 to be
increased and that of SLC4A4 decreased in PTC tissues.
The kallikrein (KLK) family comprises 15 structurally
homogeneous, trypsin-like serine protease genes [19].
KLK4 and KLK11 are known to be overexpressed in
ovarian cancer and prostate cancer, and KLK6 to be
down-regulated in breast cancer and prostate cancer [20].
Talieri et al. [21] found that KLK7 was more highly
expressed in colon cancer than in normal tissues, and they
proposed that it may be a prognostic factor in colon cancer
patients. In the present study, microarray analysis showed
KLK7 expression to be 7-fold higher in PTC tissues than in
normal tissues, a result that was confirmed by real-time
RT-PCR. Differences in KLK family gene expression in
PTC have not previously been studied and warrant further
research.
Members of the forkhead box-O (FOXO) family of
proteins are known to regulate important cellular events
such as differentiation, DNA repair, cell cycle arrest, and
apoptosis [22,23]. Karger et al. [24] reported the
cytoplasmic accumulation of Foxo3a in differentiated
thyroid cancer, in contrast to its nuclear accumulation in
normal thyroid tissue and follicular adenoma.
Cytoplasmic accumulation of Foxo3a results in increased
phospho-activation of Akt, decreased transcription of the
Foxo3a target genes p27kip and Bim, and increased
Figure 3. Cytoplasmatic accumulation of forkhead box A2 (FOXA2) in papillary thyroid cancer (PTC). (B) PTC tissues show especially
cytoplasmatic accumulation, but (A) paired normal tissues show nuclear accumulation in Foxa2 antibody staining (×100).
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expression of Gadd45a mRNA [24]. The authors
concluded that the inactivation of Foxo3a may represent a
pathogenetic mechanism for the avoidance of cancer cell
apoptosis in thyroid follicular carcinoma. Separately,
Akagi et al. [25] reported decreased expression of FOXA2
in PTC cell lines as a result of methylation of CpG islands
in the FOXA2 promoter. They also reported that forced
expression of FOXA2 inhibited cancer cell growth in PTC.
Similarly, in the present study, we showed through
microarray analysis and real-time RT-PCR that FOXA2
expression was decreased in PTC tissues compared with
normal tissues. In immunohistochemical analyses, we
showed that Foxa2 accumulated in the cytoplasm of PTC
tissues and in the nucleus in normal tissues. This suggests
that Foxa2 is transported from the nucleus to the
cytoplasm in PTC. Further study is required to determine
whether the cause of decreased FOXA2 expression is
marked cytoplasmic accumulation of FOXA2 or the
methylation of CpG islands in the promoter region of
FOXA2.
This study has certain limitations. First, the number of
subjects was small. Second, the microarray analysis may
not have been optimal. It is still not clear which
preprocessing algorithm is the most appropriate, and
some researchers argue that the statistical tools used to
analyze microarray analysis results remain insufficient.
Third, we did not test whether gene expression changes
translated into changes in protein expression. Thus,
additional studies that include a larger number of subjects
and that analyze expression at the protein level are
necessary. 
In conclusion, our study confirmed some results of
previous studies results and yielded others that were
different. Our results show that FOXA2 is down-regulated
in Korean cases of PTC as a result of the transport of
Foxa2 from the nucleus to the cytoplasm. These findings
provide insights into the molecular pathways involved in
PTC in the Korean population.
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